Alkermes(ALKS)
Focus: Alkermes is a public Dublin-headquartered biotech focused on small-molecule therapeutics across neurology, psychiatry, metabolic diseases, and addiction. The company generates $1.7B in annual revenue with a concentrated portfolio heavily dependent on flagship antipsychotic products.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
25
Should You Work at Alkermes?
AI assessmentBest suited for careers in commercial execution, supply chain, and quality assurance; risky for R&D-focused applicants given low R&D headcount and concentration risk.
Why Work Here
- Strong revenue base ($1.7B FY2025) and profitability ($356M net income) provide job security and stability absent in earlier-stage biotech.
- Deep expertise in CNS/psychiatry with a diversified pipeline of 20+ active programs across Phase 1–4, including promising Phase 3 candidates in narcolepsy, MDD, and schizophrenia.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
8 Phase 3+
LOE Risk
1 in 5yr
VIVITROL
Hiring
Stable
Revenue
$1.7B
Key Products
$273MStable
Peak12.7yr
Flagship product driving 63% of revenue; long patent life until 2039 provides runway for sustained commercial focus.
Help build intelligence for Alkermes
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.